Supplementary Figures S1-9 from Integrated Chronic In Vivo and In Vitro Screens Uncover NFIL3 as a Driver of T-cell Dysfunction

Résumé fourni par la source

Supplementary Fig. 1 Multiparametric in vitro assessment of top hits. Supplementary Fig. 2 In vitro assessment of memory phenotype and inhibitory receptor expression upon depletion of top hits. Supplementary Fig. 3 NFIL3 ablation enhances CAR T cell anti-tumor efficacy in multiple tumor models. Supplementary Fig. 4 CAR stimulation induces NFIL3 expression. Supplementary Fig. 5 Characterization of NFIL3 disruption in 4-1BB-based CAR T cells. Supplementary Fig. 6 Overexpression of NFIL3 impairs CAR T cell expansion and drives early differentiation. Supplementary Fig. 7 NFIL3 differentially regulates cytokine secretion profiles. Supplementary Fig. 8 NFIL3 drives a gene signature that is associated with poor clinical outcomes post CAR T cell therapy. Supplementary Fig. 9 Gating Strategy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.